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Abstract
Background: Clinical care of unstable spinal bone metastases in many centers often includes patient immobilization
by means of an orthopedic corset in order to prevent pathological fractures. The aim of this retrospective analysis was
to evaluate the incidence of pathological fractures after radiotherapy (RT) in patients with and without orthopedic
corsets and to assess prognostic factors for pathological fractures in patients with spinal bone metastases.
Methods: The incidence of pathological fractures in 915 patients with 2.195 osteolytic metastases in the thoracic and
lumbar spine was evaluated retrospectively on the basis of computed tomography (CT) scans between January 2000
and January 2012 depending on prescription and wearing of patient—customized orthopedic corsets.
Results: In the corset group, 6.8 and 8.0 % in no-corset group showed pathological fractures prior to RT, no significant
difference between groups was detected (p = 0.473). After 6 months, patients in the corset group showed pathological
fractures in 8.6 % and in no-corset group in 9.3 % (p = 0.709). The univariate and bivariate analyses demonstrated no
significant prognostic factor for incidence of pathological fractures in both groups.
Conclusions: In this analysis, we could show for the first time in more than 900 patients, that abandoning a general
corset supply in patients with spinal metastases does not significantly cause increased rates of pathological fractures.
Importantly, the incidence of pathological fracture after RT was small.
Background
Spinal bone metastases represent the most frequent site
of skeletal metastases [1]. The effects of bone metastases
are a major concern in everyday clinical practice and re-
sult in pain at rest and during activity, limitations in
daily life, lower performance ability, risk of pathological
fractures and neurologic deficits [2], with a significant
reduction in the patients’ quality of life (QoL). Radio-
therapy (RT) is the most common treatment option of
bone metastases in advanced tumor disease [3]. The aim
of therapy hereby is to reduce pain, to improve the func-
tionality, and to prevent complications, for example
compression of the spinal cord and pathological frac-
tures. Pathologic fractures occurred in 39 % of patients
with breast cancer, in 22 % of patients with prostate
cancer, and in 22 % of patients with bone metastases
from lung cancer or other solid tumors during 12, 15,
and 21 months of follow up, respectively [4, 5]. Conse-
quently, pathologic fractures are a significant clinical
concern in these patient populations, and preventing or
delaying fractures is an important treatment objective.
In previous retrospective studies among American and
Japanese populations, the incidence of pathologic frac-
tures in the vertebral column is estimated to range at
10 % [6, 7]. Clinical care of unstable metastases in many
centers often includes patient immobilization either by
means of an orthopedic thoracic corset or by confining
the patient to bed in order to prevent pathological frac-
tures, which further decreases patients` QoL. Accord-
ingly the incidence of pathological fractures after RT in
patients with spinal bone metastases while wearing an
orthopedic corset is still unknown. The aim of this retro-
spective analysis was to evaluate the incidence of patho-
logical fractures after RT in patients with and without
* Correspondence: harald.rief@med.uni-heidelberg.de
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Rief et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rief et al. BMC Cancer  (2015) 15:745 
DOI 10.1186/s12885-015-1797-5
orthopedic corsets and to assess prognostic factors for
incidence of pathological fractures in patients with spinal
bone metastases.
Methods
A cohort of 915 patients, was treated by RT for osteolytic
metastases of the vertebral column due to histologically di-
agnosed solid tumors at the University Clinic of Heidelberg
in the period from January 2000 until January 2012. All pa-
tients were examined using computed tomography scans
(CT) in this retrospective analysis. Inclusion criteria were
an osteolytic phenotype, location in the thoracic or lumbar
spine and a minimum duration of follow-up treatment of 6
months. A total of 2.195 bone lesions in the thoracic and
lumbar spine were identified. Bone metastases diagnoses
were verified by CT. The patient data were taken from the
Heidelberg NCT Cancer Registry and are summarized in
Table 1. Performance status was expressed using the
Karnofsky Performance Score (KPS) [8]. The specifica-
tions for an unstable vertebral body were tumor occu-
pancy of more than 60 % of the vertebral body, and
pedicle destruction [9]. Patients with an orthopedic
corset used a thoraco-lumbo-sacral orthosis (TLSO)
brace. The prescribed corset was prophylactically with
no relation to existence of a pathological fracture. The
pathological fractures were evaluated in the irradiated
spinal region. New diagnosed fractures were analyzed
prior to RT and 6 months after RT. This study was ap-
proved by the Heidelberg Ethics Committee on 22 October
2012 (nr S- 513/2012).
Table 1 Patient characteristics
Corset group No corset group All
n % n % n %
Age (mean, SD) 63.2 (+/− 11.4) 62.2 (+/−10.8) 62.7 (+/−11.1)
Gender male 236 53.4 253 53.5 489 53.4
female 206 46.6 220 46.5 426 46.6
KPS <=70 204 46.2 218 46.1 422 46.1
>70 238 53.8 255 53.9 493 53.9
Primary site NSCLC 101 22.9 206 43.5 425 46.5
Breast 219 49.6 74 15.6 175 19.1
Kidney 71 16.1 88 18.6 159 17.4
Melanoma 15 3.4 26 5.5 41 4.5
Prostate 4 0.9 13 2.8 17 1.9
Other 51 11.5 105 22.2 98 10.6
Localization Thoracic 284 64.3 279 59.0 563 61.5
Lumbar 158 35.7 194 41.0 352 38.5
Chemotherapy yes 242 54.7 260 55.1 502 54.9
no 200 45.3 212 44.9 412 45.1
Stability before RT stable 140 31.7 320 67.7 460 50.3
unstable 302 68.3 153 32.3 455 49.7
Stability after 3 months stable 152 39.8 279 79.0 449 59.2
unstable 230 60.2 79 21.0 309 40.8
Stability after 6 months stable 165 45.1 311 85.2 476 65.1
unstable 201 54.9 54 14.8 255 34.9
Bisphosphonates yes 351 79.4 296 62.6 647 70.7
no 91 20.6 177 37.4 268 29.3
Distant metastases Brain 50 11.3 77 16.3 127 13.9
Lung 74 16.7 118 25.0 192 21.0
Liver 70 15.8 116 24.5 186 20.3
Skin 11 2.5 25 5.3 36 3.9
Number of metastases solitary 189 42.8 228 48.2 417 45.6
multiple 253 57.2 245 51.8 498 54.4
SD Standard deviation; KPS Karnofsky performance score; RT Radiotherapy
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Statistical analysis
The empirical distribution of continuous variables is de-
scribed by the number of observations, mean and standard
deviation; the description of categorical variables includes
the number and percentage of patients belonging to the
relevant categories. We estimated number of observations
of pathological fractures before and 6 months after RT and
compared them between groups according to the chi-
square test. The univariate log-rank test was used to
evaluate the prognostic importance for occurrence of
pathological fractures of gender, Karnofsky performance
score, non-small cell lung cancer (NSCLC), breast cancer,
kidney cancer, localization of metastases, chemotherapy
prior to RT, stability prior to RT, stability after 3 months,
stability after 6 months, bisphosphonates, and number of
bone metastases. Results were reported as p-values of the
logrank tests. Bivariate analysis was performed to de-
tect factors independently associated with pathological
fractures using a Cox regression model. This regres-
sion analysis was performed including gender (male),
Karnofsky performance score (<=70), NSCLC (no pri-
mary), breast cancer (no primary), kidney cancer (no
primary), localization of metastases (thoracic), chemo-
therapy prior to RT (no chemotherapy), stability prior
to RT (unstable), stability after 3 months (unstable), stability
after 6 months (unstable), bisphosphonates (no bispho-
sphonates), and number of bone metastases (solitary metas-
tasis). The results are reported as p-values, odds ratios and
95 % confidence intervals (CI). For all analyses, a p-value of
0.05 or less was considered significant. All statistical ana-
lyses were done using the SAS software version 9.3 (SAS
Institute, Cary, NC, USA).
Radiotherapy
RT was performed in the Department of Radiation Oncol-
ogy at the Heidelberg University Clinic. After virtual simu-
lation was performed to plan the radiation schedule, RT
was carried out over a dorsal photon field of the 6MV en-
ergy range. The photon field covered the specific vertebral
body affected as well as the ones immediately above and
below. The median individual dose in all patients was
3 Gy (range 2–3 Gy), the median total dose 30 Gy (range
20–35 Gy). The individual and total doses were decided
separately for each individual patient, depending on hist-
ology, the patient’s general state of health, the current sta-
ging, and the corresponding prognosis.
Results
The mean follow-up was 6.3 months for both groups. Of
all patients, 31.7 % (140 patients) in the corset group
and 67.7 % (320 patients) in the no-corset group were
classified as stable prior to RT, 79.4 % (n = 351) and 62.6 %
(n = 296) of the corset and no corset group were also
treated with bisphosphonates. Considering the number of
metastases, 57.2 % (n = 253) in the corset group and 51.8 %
(n = 245) in the no corset group showed multiple metasta-
ses. The incidence of unstable metastases was higher in the
corseted group (68.3 %) compared to the non-corseted
group (32.3 %) prior to RT (p < 0.01). The incidence of
pathological fractures prior to RT was 7.4 % in all patients.
In the corset group, 6.8 and 8.0 % in no-corset group
showed pathological fractures prior to RT, no significant
difference between groups was detected (p = 0.473). After
6 months, the fracture rate was in total 9.0 % for all pa-
tients and correspond 1.6 % new diagnosed fractures. Pa-
tients in corset group showed in 8.6 % and in no-corset
group in 9.3 % pathological fractures (correspond 1.8 and
1.3 % new diagnosed fractures) (p = 0.709). The thoracic
spine showed more fractures significantly (Table 2).
The univariate and bivariate analyses identified no sig-
nificant prognostic factors for incidence of pathological
fractures in both groups (Tables 3 and 4).
Discussion
Bone metastases are common in patients with advanced
malignancies. The spinal column is the most common
site of bone metastases. Metastatic vertebral body col-
lapse is one of the major causes of severe back pain and
Table 2 Pathological fractures before and after RT
All Corset group No corset group p-value
n % n % n % between groups
Pathological fracture yes 68 7.4 30 6.8 38 8.0
before RT no 847 92.6 412 93.2 435 92.0 0.473
thoracic 42 61.8 22 73.3 20 52.6
lumbar 26 38.2 8 26.7 18 47.4 0.081
Pathological fracture yes 82 9.0 38 8.6 44 9.3
after 6 months no 833 91.0 404 91.4 429 90.7 0.709
thoracic 51 62.2 28 73.7 23 52.3
lumbar 31 37.8 10 26.3 21 47.7 0.046
Pathological fractures before and 6 months after RT in corset and no corset group
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neurologic compromise. Therefore, prevention of patho-
logic fractures is of clinical importance to maintain pa-
tients` QoL.
Bone metastases from solid tumors can dramatically
increase bone resorption, resulting in skeletal complica-
tions such as pathologic fractures (10–20 % of patients),
spinal cord compression (5 % of patients), hypercalcemia
of malignancy (10–15 % of patients), severe bone pain
requiring palliative RT, and represent important clinical
issues. Fractures may cause severe bone pain, limit mo-
bility, and require surgery and hospitalization for treat-
ment [10, 11].
Our results showed a pathological fracture rate of 7.4 %
in all patients. First, we compared between orthopedic cor-
set and no-corset groups to examine the effectiveness of
the corset for prevention of a pathological fracture. The
corset group with 6.8 and 8.0 % in the no-corset group did
not differ between groups. Additionally, after 6 months no
significant difference between groups was detected. In a
recent trial, the results showed a pathological fracture rate
in 18 % of the vertebral bodies prior to RT. New fractures
up to 6 months after therapy were seen in 2 % of all cases
[12]. This 6-months fracture rate was comparable to our
results. In previous retrospective studies among American
and Japanese populations, the incidence of pathologic frac-
tures in the vertebral column ranges around 10 % [6, 7]
and corresponds to our findings. In a further analysis by
Saad et al. [13], the risk of pathological fracture in associ-
ation with lung cancer is given at 17 %; this finding, how-
ever, was made relative to the entire skeletal system.
Pathological fractures are a frequently encountered event;
fractures of the vertebral body following RT, on the other
hand, are rarely reported. In our results, the thoracic spine
showed significant more fractures 6 months after RT.
However, 61.5 % of metastases were detected in the thor-
acic spine. The rib cage and sternum can provide add-
itional structural support, but we could not detect any
influence to our results. In the clinical treatment of spinal
metastases, many advances have been made in the ability
to determine both the size and location of vertebral lesions
[14, 15]. Elevated risk of pathologic vertebral body fracture
may not, by itself, justify prophylactic stabilization, as many
fractured vertebrae are stable or fractured in a manner that
does not compromise the spinal canal [2]. Increased tumor
size, lower BMD, increased load, and pedicle involvement
elevate the risk of burst fracture prior to endplate failure
[15]. The study by Taneichi et al. [9] defines the risk factors
for fractures of the vertebral bodies caused by osteolytic
metastases and rates the estimated fractures according to
different types of metastatic involvement, establishing
Table 3 Univariate analysis of prognostic factors for incidence
of pathological fractures
Factor Corset group No corset group
p-value p-value
Gender 0.357 0.642
KPS 0.402 0.819
NSCLC 0.101 0.184
Breast cancer 0.496 0.091
Kidney cancer 0.072 0.195
Localization 0.205 0.342
Chemotherapy 0.454 0.379
Stability before RT 0.268 0.677
Stability after 3 months 0.513 0.614
Stability after 6 months 0.202 0.402
Bisphosphonates 0.183 0.420
Number of metastases 0.145 0.229
Table 4 Bivariate analysis of prognostic factors for incidence of pathological fractures
All Corset group No corset group
OR 95 % CI p-value OR 95 % CI p-value OR 95 % CI p-value
Gender 0.797 0.503–1.262 0.333 0.727 0.369–1.434 0.358 0.862 0.461–1.612 0.642
KPS 0.843 0.535–1.327 0.461 0.753 0.387–1.465 0.403 0.930 0.500–1.731 0.819
NSCLC 0.604 0.376–0.969 0.036 0.566 0.285–1.126 0.105 0.645 0.336–1.237 0.186
Breast cancer 0.562 0.284–1.113 0.098 0.745 0.318–1.746 0.498 0.369 0.111–1.225 0.103
Kidney cancer 1.071 0.595–1.928 0.818 2.008 0.928–4.345 0.076 0.534 0.204–1.398 0.202
Localization 0.970 0.607–1.548 0.897 0.618 0.292–1.308 0.208 1.351 0.725–2.517 0.343
Chemotherapy 1.020 0.647–1.609 0.931 1.295 0.657–2.555 0.455 1.329 0.704–2.511 0.381
Stability before RT 0.937 0.595–1.474 0.777 0.647 0.298–1.406 0.271 1.155 0.586–2.276 0.677
Stability after 3 months 0.993 0.594–1.660 0.980 0.776 0.363–1.660 0.514 1.266 0.505–3.174 0.614
Stability after 6 months 0.939 0.537–1.642 0.826 0.587 0.256–1.343 0.207 1.682 0.493–5.740 0.406
Bisphosphonates 0.939 0.573–1.538 0.803 0.606 0.288–1.274 0.186 1.313 0.676–2.550 0.421
Number of metastases 1.314 0.826–2.090 0.249 1.689 0.829–3.442 0.149 0.683 0.365–1.277 0.232
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criteria for assessing the risk of vertebral-body fractures.
The risk factors for vertebral-body fractures in the thoracic
region (T1-T10) are the tumor size and the degree of de-
struction of the costovertebral joint; in the thoracolumbar
and lumbar region (T10-L5), it is the tumor size and degree
of pedicle destruction that are the main factors [16]. There-
fore, Taneichi et al. [9] conducted radiographic analyses of
patients with metastatic spinal tumors and concluded that
destruction of the costovertebral joint was one of the major
risk factors of vertebral collapse in the thoracic and lumbar
spine. Certainly, there are multiple scoring systems to as-
sess spinal instability in the literature [17, 18]. We used the
Taneichi Score because of the practicability and easy appli-
ance in the clinical practice. As a main concern, this scoring
system constitutes a simple method for classifying osteo-
lytic metastases in vertebral bodies as „stable“or „unsta-
ble“by definition of risk factors such as tumor size and the
degree of costovertebral joint destruction for the thoracic
region (Th 1 to 10) and tumor size and the degree of ped-
icle destruction for the lumbar region (Th 11 to L5), which
is why this score is employed in this evaluation. Reduc-
tions in fracture risk following bisphosphonate treat-
ment are also frequently disproportionate to changes in
bone density [19, 20]. Bisphosphonates were found to
reduce the overall risk of skeletal complications by 14 %
and to reduce the incidence of fractures by 28 to 37 % [21].
According to our data, both groups had a high bisphospho-
nates rate so that this bias was negligible small. Recently,
however, zoledronic acid has demonstrated efficacy in the
management of bone pain and prevention of SREs, includ-
ing pathologic fractures [19]. However, bisphosphonate
therapy was not a prognostic factor for pathological frac-
tures according to our results.
Pathological fractures play a major role in everyday
clinical practice. Common clinical care of unstable me-
tastases or existing fractures often includes patient
immobilization either by means of an orthopedic corset
or by confining the patient to bed in order to prevent
pathological fractures, which further decreases patients`
quality-of-life (QoL). Secondly, the pain, which can be
severe, is mechanical in origin, and frequently the pa-
tient is only comfortable when lying still. However, no
data regarding the appearance of pathological fractures
by wearing a corset exist so far. According to our results,
patients without an orthopedic corset did not have an
increased risk of pathological fractures after RT. In both
groups unstable metastases were detected, while the
number in the corset group was significantly higher. In
our opinion, wearing a corset also maintains some disad-
vantages in palliative patients: atrophy of the paraverteb-
ral musculature, limitation in mobility and reduction of
the QoL. The importance of the corset in stability-
endangering metastases was discussed up to now con-
troversially, whether thereby fractures can be avoided.
The vertical pressure load on the vertebral body also
continues with corset, only axial movements can be de-
creased. Some prognostic factors as mentioned above
are already known, our analysis could not identify prog-
nostic factors for both groups. Only no NSCLC as primary
site in all patients was significant, however, this result was
affected due to a large number of evaluated NSCLC pa-
tients. Therefore, this point cannot be derived a factor.
The main limitation of this study was the higher incidence
of unstable vertebral bodies in patients in the corseted
group (68.3 %) compared to the non-corseted group
(32.3 %). Further limitations were the variety of primary
tumors and the exclusion of patients presenting with cer-
vical spine metastases. Among the strengths of our ana-
lysis were the large cohort and the very pertinent clinical
question for patients with spinal bone metastases. This
was, to our knowledge, the very first analysis to determine
if a corset had any utility in preventing the incidence of
pathologic fractures after routine radiotherapy.
Conclusion
In this analysis, we could show for the first time in more
than 900 patients, that by omission of corsets the fracture
rate was not increased. Importantly, the incidence of a
pathological fracture after RT was seldom. Large random-
ized trials are necessary to confirm these findings.
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